SemPresto — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

SemPresto is addressing a critical gap in anaphylaxis management: patient non-adherence to carrying bulky, traditional epinephrine autoinjectors. The company has developed a compact autoinjector that attaches directly to a smartphone case, leveraging the near-constant proximity of a phone to ensure the medication is always accessible. This consumer-centric hardware solution targets the large and growing population with severe allergies, where delayed epinephrine administration is a leading cause of poor outcomes. By integrating emergency treatment into daily life, SemPresto aims to improve real-world adherence and save lives.

Allergy & ImmunologyEmergency Medicine

Technology Platform

A miniaturized autoinjector platform designed for physical attachment to smartphone cases, aiming to ensure constant carriage of emergency epinephrine.

Opportunities

The large and growing population with severe allergies, combined with high rates of non-adherence in carrying existing bulky autoinjectors, presents a clear addressable market.

The company's smartphone-integration strategy aligns perfectly with the consumerization of healthcare and could drive superior patient compliance.

The platform could be expanded to other emergency medications, creating a pipeline of smartphone-attached rescue therapies.

Risk Factors

The company faces significant regulatory risk in obtaining FDA clearance for its novel device form factor.

It must also overcome entrenched competition from established autoinjector brands and convince the medical community to adopt a new paradigm.

Successful commercialization depends on solving the engineering challenge of universal phone case attachment and securing favorable insurance reimbursement.

Competitive Landscape

SemPresto competes directly with dominant, branded epinephrine autoinjectors like Viatris's EpiPen and Kaléo's Auvi-Q, which have deep market penetration and sales infrastructure. It also competes with generic autoinjectors on price and newer digital health solutions that offer connectivity features. Its primary competitive angle is form-factor convenience and adherence, not drug efficacy or digital connectivity.

More companies in Drug Delivery & Formulation →More companies in United States →